A prospective, double blind, randomised, multicentre trial to evaluate the efficacy of combination therapy, which comprised imidafenacin and an alpha-blocker, with monotherapy, which comprised an alpha-blocker, at managing men with lower urinary tract symptoms (LUTS) and storage symptoms
Latest Information Update: 06 Nov 2017
At a glance
- Drugs Alfuzosin (Primary) ; Imidafenacin (Primary)
- Indications Benign prostatic hyperplasia; Overactive bladder
- Focus Therapeutic Use
- 06 Nov 2017 New trial record